Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Improved Prostate Cancer Diagnosis with AI-powered Workflows

Proscia
By Author Proscia | March 12, 2021

Philadelphia-based Proscia and Ibex Medical Analytics, Tel Aviv, Israel, have entered into a strategic partnership to support pathologists in detecting prostate cancer, the second leading cause of cancer death among men in the United States. Through the collaboration, the partners will advance the use of computationally enabled workflows leveraging AI, which drive accuracy, efficiency, and quality gains in routine pathology diagnosis.

Our website uses cookies. By using this site, you agree to its use of cookies.